Hoth Therapeutics’ HT-ALZ achieves positive preclinical end points in study

Hoth Therapeutics announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer’s Disease, or AD, achieved positive preclinical end points in a study conducted at Washington University, St. Louis. Subjects treated with HT-ALZ show improvement on several tests of cognitive function, including spatial learning and memory, sensorimotor gating, and contextual associative memory. HT-ALZ showed positive benefits with reducing anxiety- like behavior in mice. AD is a neurodegenerative disease that is characterized by aggregates of amyloid beta (Abeta) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease, such as dementia.